BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.

Trial Details

NCT ID
NCT06746519
Phase
PHASE1 / PHASE2
Sponsor
Chen Suning
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Have been fully informed about the study and have voluntarily signed the ICF;
  • Patients with newly diagnosed primary AML according to the 2022 World Health Organization (WHO) criteria (Groups A and B) or patients with relapsed…
  • Peripheral blood leukocyte count ≤ 25 x 109/L (limited to patients enrolled in groups B and C, where hydroxyurea is allowed to control peripheral b…
  • Aged 18 years or older;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →